Newer heart valve replacement treatment increased in the U.S. in wealthy, metro areas

(NewMediaWire) – October 21, 2021 – DALLAS – Research Highlights:

  • Despite the increase in the number of health centers in the U.S. performing the newer, minimally invasive heart valve procedure called TAVR (transcatheter aortic valve replacement), the expansion has not occurred equitably in communities across the country, according to new research published today in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
  • TAVR is a newer surgical procedure to replace a diseased valve in the heart. Through a catheter, a new replacement heart valve is placed inside the old, damaged valve and takes over the work of regulating blood flow in the heart. The procedure is a beneficial option for people who may not have been considered for traditional valve replacement via open-heart surgery because it is performed through small openings in the chest, leaving all the chest bones in place, thereby avoiding the lengthy recovery time and additional risks associated with open-heart surgery.
  • In the study conducted by the University of Pennsylvania in Philadelphia, researchers found that during the initial growth phase of TAVR programs (health centers with trained staff and specialized equipment to provide TAVR) between 2012 and 2018, U.S. hospitals in wealthier communities (based on median income levels) and metropolitan areas were more likely to start TAVR programs, while hospitals in poorer or rural communities were less likely to start TAVR programs.
  • The number of TAVR procedures were 1.19% lower for each 1% increase in patients with markers of lower socioeconomic status.
  • The analysis indicates just over 98% of the new TAVR programs during the 6-year study period opened in metropolitan areas and were in metropolitan areas that had pre-existing TAVR programs 50% of the time.
  • These findings highlight geographic and socioeconomic inequities in the growth and dispersion of the advanced TAVR procedure. The unequal introduction of this novel technology and treatment appears to be one factor contributing to health care inequities among socioeconomically disadvantaged people, the authors write.

Additional Resources:

Statements and conclusions of studies published in the American Heart Association’s scientific journals are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on, Facebook, Twitter or by calling 1-800-AHA-USA1.


For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173

Bridgette McNeill:

For Public Inquiries: 1-800-AHA-USA1 (242-8721) and